PharmaMar has signed an exclusive licensing agreement with Seattle Genetics Inc. under which Seattle Genetics receives exclusive worldwide rights to certain PharmaMar proprietary molecules for the development, manufacture, and commercialization of antibody-drug conjugates (ADCs) and/or other drug conjugates incorporating PharmaMar payloads. According to the terms of the agreement, PharmaMar receives an upfront payment of $5 million on signing, followed…